Targeting Cardiac hypertrophy: Toward a causal heart failure therapy

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 4, 2014, Pages 293-305

  Bisping, Egbert ^a,b   Wakula, Paulina ^a,b   Poteser, Michael ^c,d   Heinzel, Frank R ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Institute of Biophysics   (Austria)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AKT; Angiotensin II; Angiotensin receptor blockers; Beta blockers; Biased agonists; Calcineurin; Calcium; Camkii; CGMP; Guanylatecyclase stimulators; Heart failure; Hypertension; Hypertrophy; Left ventricular; NFAT; Nitric oxide; Reactive oxygen species; Remodeling; Signaling; Vitamin

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; BETA ADRENERGIC RECEPTOR; CYCLIC GMP; CYTOKINE; ENKEPHALINASE INHIBITOR; FINERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PF 03882845; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERCA2A PROTEIN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT;

ADENO ASSOCIATED VIRUS; ADRENERGIC SYSTEM; ARTICLE; EXPERIMENTAL THERAPY; GENE TRANSFER; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; META ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIPELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSCRIPTION REGULATION; VALIDATION STUDY; CARDIOMEGALY; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; HEART VENTRICLE REMODELING; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANTIHYPERTENSIVE AGENTS; CARDIOMEGALY; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; VENTRICULAR REMODELING;

EID: 84928116551     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000126     Document Type: Article

References (231)

1. Buja LM, Ferrans VJ, Maron BJ, et al. Intracytoplasmic junctions in cardiac muscle cells. Am J Pathol. 1974;74:613-647.
2. Opie LH, Commerford PJ, Gersh BJ, et al. Controversies in ventricular remodelling. Lancet. 2006;367:356-367.
3. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: Mechanisms: part 1 of 2. Circulation. 2013;128:388-400.
4. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
5. Sawada K, Kawamura K. Architecture of myocardial cells in human cardiac ventricles with concentric and eccentric hypertrophy as demonstrated by quantitative scanning electron microscopy. Heart Vessels. 1991;6:129-142.
6. Gerdes AM, Kellerman SE, Moore JA, et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation. 1992;86:426-430.
7. Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol. 1995; 27:849-856.
8. Kuo PL, Lee H, Bray MA, et al. Myocyte shape regulates lateral registry of sarcomeres and contractility. Am J Pathol. 2012;181:2030-2037.
9. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
10. Dorn GW, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res. 2003;92:1171-1175.
11. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
12. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
13. Verdecchia P, Carini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol. 2001;38:1829-1835.
14. Lonn E, Mathew J, Pogue J, et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur J Cardiovasc Prev Rehabil. 2003;10:420-428.
15. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
16. Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur Heart J. 2005;26:1790-1796.
17. Krishnamoorthy A, Brown T, Ayers CR, et al. Progression from normal to reduced left ventricular ejection fraction in patients with concentric left ventricular hypertrophy after long-term follow-up. Am J Cardiol. 2011;108:997-1001.
18. Shafazand M, Rosengren A, Lappas G, et al. Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993- 2004: A study of 175, 216 patients with a first acute myocardial infarction in Sweden. Eur J Heart Fail. 2011;13:135-141.
19. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005;111:3290-3295.
20. van Bilsen M, Smeets PJ, Gilde AJ, et al. Metabolic remodelling of the failing heart: The cardiac burn-out syndrome? Cardiovasc Res. 2004;61: 218-226.
21. Mohammed SF, Ohtani T, Korinek J, et al. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation. 2010;122:370-378.
22. Graham HK, Trafford AW. Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure. Am J Physiol Heart Circ Physiol. 2007;292 1364-1372.
23. Skrbic B, Bjornstad JL, Marstein HS, et al. Differential regulation of extracellular matrix constituents in myocardial remodeling with and without heart failure following pressure overload. Matrix Biol. 2013;32:133-142.
24. Xu XH, Xu J, Xue L, et al. VEGF attenuates development from cardiac hypertrophy to heart failure after aortic stenosis through mitochondrial mediated apoptosis and cardiomyocyte proliferation. J Cardiothorac Surg. 2011;6:54.
25. Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation. 1975;51:606-613.
26. Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32:1454-1459.
27. Kunisek J, Zaputovic L, Mavric Z, et al. Influence of the type and degree of left ventricular hypertrophy on the prevalence of ventricular arrhythmias in patients with hypertensive heart disease. Med Klin (Munich). 2008;103:705-711.
28. Bayes-Genis A, Guindo J, Vinolas X, et al. Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Am J Cardiol. 1995;76:54-59.
29. Souders CA, Borg TK, Banerjee I, et al. Pressure overload induces early morphological changes in the heart. Am J Pathol. 2012;181:1226-1235.
30. French BA, Kramer CM. Mechanisms of post-infarct left ventricular remodeling. Drug Discov Today Dis Mech. 2007;4:185-196.
31. Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000;101:2863-2869.
32. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109:3050-3055.
33. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
34. Kass DA, Baughman KL, Pak PH, et al. Reverse remodeling from cardiomyoplasty in human heart failure. External constraint versus active assist. Circulation. 1995;91:2314-2318.
35. Sachse FB, Torres NS, Savio-Galimberti E, et al. Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy. Circ Res. 2012;110:588-597.
36. Larstorp AC, Okin PM, Devereux RB, et al. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; the LIFE study. Am J Hypertens. 2012;25:1101-1109.
37. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-2356.
38. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
39. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292: 2343-2349.
40. Okin PM, Devereux RB, Gerdts E, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation. 2006;113:1588-1596.
41. Ottaviano FG, Yee KO. Communication signals between cardiac fibroblasts and cardiac myocytes. J Cardiovasc Pharmacol. 2011;57: 513-521.
42. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575.
43. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev. 2007;87: 1285-1342.
44. Kehat I, Davis J, Tiburcy M, et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res. 2011;108:176-183.
45. Toischer K, Rokita AG, Unsold B, et al. Differential cardiac remodeling in preload versus afterload. Circulation. 2010;122:993-1003.
46. Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: The CARE study. J Am Coll Cardiol. 2003;42:1446-1453.
47. Shah AM, Shin SH, Takeuchi M, et al. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail. 2012;14:185-192.
48. Hingtgen SD, Li Z, Kutschke W, et al. Superoxide scavenging and Akt inhibition in myocardium ameliorate pressure overload-induced NFkappaB activation and cardiac hypertrophy. Physiol Genomics. 2010; 41:127-136.
49. Nikolaev VO, Moshkov A, Lyon AR, et al. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science. 2010;327:1653-1657.
50. Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17.
51. Giannetta E, Isidori AM, Galea N, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: A randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012;125:2323-2333.
52. Zouein FA, de Castro Bras LE, da Costa DV, et al. Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol. 2013;62:13-21.
53. Bernardo BC, Weeks KL, Pretorius L, et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128:191-227.
54. Perrino C, Naga Prasad SV, Mao L, et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006;116:1547-1560.
55. Weeks KL, Gao X, Du XJ, et al. Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail. 2012;5: 523-534.
56. Tamura T, Said S, Harris J, et al. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation. 2000;102:253-259.
57. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
58. Krause MW, Fonseca VA, Shah SV. Combination inhibition of the renin-angiotensin system: Is more better? Kidney Int. 2011;80:245-255.
59. Noor N, Patel CB, Rockman HA. Beta-arrestin: A signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol. 2011;51:534-541.
60. Soergel DG, Subach RA, Cowan CL, et al. First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2013;53:892-899.
61. Monasky MM, Taglieri DM, Henze M, et al. The beta-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium. Am J Physiol Heart Circ Physiol. 2013;305:856-866.
62. Chan AK, Sanderson JE, Wang T, et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007;50:591-596.
63. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838.
64. Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003;42:1666-1673.
65. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341:709-717.
66. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
67. Cittadini A, Monti MG, Isgaard J, et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res. 2003;58:555-564.
68. Orena S, Maurer TS, She L, et al. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol. 2013;4:115.
69. Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385-1403.
70. Yang L, Cai X, Liu J, et al. CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kalpha-Akt signaling. PLoS One. 2013;8:62373-.
71. Morimoto T, Sunagawa Y, Kawamura T, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest. 2008;118:868-878.
72. Calvert JW, Elston M, Nicholson CK, et al. Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation. 2010;122:11-19.
73. Liu W, Zi M, Tsui H, et al. A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail. 2013;6:833-844.
74. Erdmann E, Semigran MJ, Nieminen MS, et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2013;34:57-67.
75. Thandapilly SJ, Louis XL, Behbahani J, et al. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats. Hypertens Res. 2013;36:866-872.
76. Dai DF, Chen T, et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol. 2011; 58:73-82.
77. Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330-340.
78. Boerrigter G, Soergel DG, Violin JD, et al. TRV120027, a novel betaarrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail. 2012;5:627-634.
79. Lai NC, Roth DM, Gao MH, et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation. 2004;110:330-336.
80. Segura J, Salazar J, Ruilope LM. Dual neurohormonal intervention in CV disease: Angiotensin receptor and neprilysin inhibition. Expert Opin Investig Drugs. 2013;22:915-925.
81. Jay SM, Murthy AC, Hawkins JF, et al. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation. 2013;128:152-161.
82. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet. 2013;381:29-39.
83. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J. 2013;34:2453-2463.
84. Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: A comparison with spironolactone. Eur Heart J. 2008;29:2171-2179.
85. Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- And active-controlled phase 2 trial. Circulation. 2011;124:1945-1955.
86. Minnaard-Huiban M, Emmen JM, Roumen L, et al. Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. Endocrinology. 2008;149:28-31.
87. Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013;31:2085-2093.
88. Andersen K, Hartman D, Peppard T, et al. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: A phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2012;14:580-587.
89. Pouleur AC, Uno H, Prescott MF, et al. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2011;12:483-490.
90. Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32:1227-1234.
91. Gheorghiade M, Bohm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: The ASTRONAUT randomized trial. JAMA. 2013;309:1125-1135.
92. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367: 2204-2213.
93. Oh KS, Oh BK, Park CH, et al. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy- 6-piperazino triazine (DW1865). Eur J Pharmacol. 2013;702:218-226.
94. Duan C, Liu M, Zhang J, et al. RASSF1A: A potential novel therapeutic target against cardiac hypertrophy. Prog Biophys Mol Biol. 2013;113: 284-288.
95. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: A meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-1091.
96. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of betablocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007;104:16657-16662.
97. Gao Y, Vanhoutte PM. Nebivolol: An endothelium-friendly selective beta1-adrenoceptor blocker. J Cardiovasc Pharmacol. 2012;59:16-21.
98. Rengo G, Lymperopoulos A, Zincarelli C, et al. Myocardial adenoassociated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation. 2009;119:89-98.
99. Casey LM, Pistner AR, Belmonte SL, et al. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res. 2010;107:532-539.
100. Raake PW, Schlegel P, Ksienzyk J, et al. AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J. 2013;34:1437-1447.
101. HedayatM, Mahmoudi MJ, Rose NR, et al. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010;15:543-562.
102. Melendez GC, McLarty JL, Levick SP, et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56:225-231.
103. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther. 2010;127:295-314.
104. Daien CI, Fesler P, du CG, et al. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72: 881-887.
105. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109: 1594-1602.
106. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo- controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
107. Lai NC, Gao MH, Tang E, et al. Pressure overload-induced cardiac remodeling and dysfunction in the absence of interleukin 6 in mice. Lab Invest. 2012;92:1518-1526.
108. Manukyan MC, Alvernaz CH, Poynter JA, et al. Interleukin-10 protects the ischemic heart from reperfusion injury via the STAT3 pathway. Surgery. 2011;150:231-239.
109. Gullestad L, Ueland T, Vinge LE, et al. Inflammatory cytokines in heart failure: Mediators and markers. Cardiology. 2012;122:23-35.
110. Zouein FA, Kurdi M, Booz GW. Dancing rhinos in stilettos: The amazing saga of the genomic and nongenomic actions of STAT3 in the heart. JAKSTAT. 2013;2:24352.
111. Liu W, Zi M, Chi H, et al. Deprivation of MKK7 in cardiomyocytes provokes heart failure in mice when exposed to pressure overload. J Mol Cell Cardiol. 2011;50:702-711.
112. Wang Y, Su B, Sah VP, et al. Cardiac hypertrophy induced by mitogenactivated protein kinase kinase 7, a specific activator for c-Jun NH2- Terminal kinase in ventricular muscle cells. J Biol Chem. 1998;273: 5423-5426.
113. Braz JC, Bueno OF, Liang Q, et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 2003;111:1475-1486.
114. Liao P, Georgakopoulos D, Kovacs A, et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A. 2001;98:12283-12288.
115. Dhalla NS, Mueller AL. Protein kinases as drug development targets for heart disease therapy. Pharmaceuticals. 2010;3:2111-2145.
116. Melloni C, Sprecher DL, Sarov-Blat L, et al. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am Heart J. 2012;164:646-653.
117. Sadoshima J, Xu Y, Slayter HS, et al. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
118. Blaauw E, van Nieuwenhoven FA, Willemsen P, et al. Stretch-induced hypertrophy of isolated adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol. 2010;299:780-787.
119. Sadoshima J, Jahn L, Takahashi T, et al. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J Biol Chem. 1992;267: 10551-10560.
120. Schnitzler M, Storch U, Meibers S, et al. Gq-coupled receptors as mechanosensors mediating myogenic vasoconstriction. EMBO J. 2008;27:3092-3103.
121. Geier C, Perrot A, Ozcelik C, et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation. 2003;107:1390-1395.
122. Li R, Wu Y, Manso AM, et al. Beta1 integrin gene excision in the adult murine cardiac myocyte causes defective mechanical and signaling responses. Am J Pathol. 2012;180:952-962.
123. Reardon DA, Neyns B, Weller M, et al. Cilengitide: An RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011;7:339-354.
124. Spassova MA, Hewavitharana T, Xu W, et al. A common mechanism underlies stretch activation and receptor activation of TRPC6 channels. Proc Natl Acad Sci U S A. 2006;103:16586-16591.
125. Maroto R, Raso A, Wood TG, et al. TRPC1 forms the stretch-activated cation channel in vertebrate cells. Nat Cell Biol. 2005;7:179-185.
126. Dietrich A, Kalwa H, Storch U, et al. Pressure-induced and storeoperated cation influx in vascular smooth muscle cells is independent of TRPC1. Pflugers Arch. 2007;455:465-477.
127. Gottlieb P, Folgering J, Maroto R, et al. Revisiting TRPC1 and TRPC6 mechanosensitivity. Pflugers Arch. 2008;455:1097-1103.
128. Poteser M, Schleifer H, Lichtenegger M, et al. PKC-dependent coupling of calcium permeation through transient receptor potential canonical 3 (TRPC3) to calcineurin signaling in HL-1 myocytes. Proc Natl Acad Sci U S A. 2011;108:10556-10561.
129. Schleifer H, Doleschal B, Lichtenegger M, et al. Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca(2+) entry pathways. Br J Pharmacol. 2012;167: 1712-1722.
130. Kiyonaka S, Kato K, Nishida M, et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci U S A. 2009;106:5400-5405.
131. Schaub MC, Hefti MA, Zaugg M. Integration of calcium with the signaling network in cardiac myocytes. J Mol Cell Cardiol. 2006;41: 183-214.
132. Makarewich CA, Correll RN, Gao H, et al. A caveolae-targeted L-type Ca(2)+ channel antagonist inhibits hypertrophic signaling without reducing cardiac contractility. Circ Res. 2012;110:669-674.
133. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
134. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: The prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001;104:1248-1254.
135. de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J. 2000;139:185-194.
136. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374-384.
137. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
138. Sacherer M, Sedej S, Wakula P, et al. JTV519 (K201) reduces sarcoplasmic reticulum Ca(2)(+) leak and improves diastolic function in vitro in murine and human non-failing myocardium. Br J Pharmacol. 2012; 167:493-504.
139. Lehnart SE, Terrenoire C, Reiken S, et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc Natl Acad Sci U S A. 2006;103:7906-7910.
140. van Oort RJ, Respress JL, Li N, et al. Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model. Hypertension. 2010;55:932-938.
141. Sedej S, Schmidt A, Denegri M, et al. Subclinical abnormalities in sarcoplasmic reticulum Ca2+ release promote eccentric myocardial remodeling and pump failure death in response to pressure overload. J Am Coll Cardiol. 2014;63:1569-1579.
142. Kaneko N, Matsuda R, Hata Y, et al. Pharmacological characteristics and clinical applications of K201. Curr Clin Pharmacol. 2009;4: 126-131.
143. Kraus C, Rohde D, Weidenhammer C, et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol. 2009;47:445-455.
144. Pleger ST, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med. 2011;3:92-64.
145. Beeri R, Chaput M, Guerrero JL, et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail. 2010;3:627-634.
146. Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313.
147. Sipido KR, Vangheluwe P. Targeting sarcoplasmic reticulum Ca2+ uptake to improve heart failure: Hit or miss. Circ Res. 2010;106:230-233.
148. Verdonck F, Mubagwa K, Sipido KR. [Na(+)] in the subsarcolemmal "fuzzy" space and modulation of [Ca(2+)](i) and contraction in cardiac myocytes. Cell Calcium. 2004;35:603-612.
149. Karmazyn M, Kilic A, Javadov S. The role of NHE-1 in myocardial hypertrophy and remodelling. J Mol Cell Cardiol. 2008;44:647-653.
150. Mentzer RM Jr, Bartels C, Bolli R, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg. 2008;85:1261-1270.
151. Avkiran M, Cook AR, Cuello F. Targeting Na+/H+ exchanger regulation for cardiac protection: A RSKy approach? Curr Opin Pharmacol. 2008;8:133-140.
152. Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133:311-323.
153. Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. 2008;295:2149-2155.
154. Fischer TH, Neef S, Maier LS. The Ca-calmodulin dependent kinase II: A promising target for future antiarrhythmic therapies? J Mol Cell Cardiol. 2013;58:182-187.
155. Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002; 110:479-488.
156. Bush EW, McKinsey TA. Protein acetylation in the cardiorenal axis: The promise of histone deacetylase inhibitors. Circ Res. 2010;106:272-284.
157. Kee HJ, Sohn IS, Nam KI, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006;113:51-59.
158. Kao YH, Liou JP, Chung CC, et al. Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol. 2013;168:4178-4183.
159. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15:3958-3969.
160. McKinsey TA. Isoform-selective HDAC inhibitors: closing in o n translational medicine for the heart. J Mol Cell Cardiol. 2011;51:491-496.
161. Sayed D, Hong C, Chen IY, et al. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007;100:416-424.
162. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13:613-618.
163. da Costa Martins PA, Salic K, GladkaMM, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol. 2010;12:1220-1227.
164. Thum T. MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med. 2012;4:3-14.
165. Bernardo BC, Gao XM, Winbanks CE, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A. 2012;109: 17615-17620.
166. Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2013;2: 000078.
167. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-248.
168. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA. 2005;293:1338-1347.
169. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-1149.
170. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342: 154-160.
171. Deleted in proof.
172. Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003;35:398-403.
173. Pan XD, Zeng ZH, Liang LY, et al. The effects of simvastatin on left ventricular hypertrophy and left ventricular function in patients with essential hypertension. Clin Exp Hypertens. 2011;33:558-564.
174. Folkeringa RJ, de VC, Pinto YM, et al. No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension: A prospective randomised open-label study with blinded endpoint assessment. Int J Cardiol. 2010;145:156-158.
175. Bauersachs J, Stork S, Kung M, et al. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: A randomized placebo-controlled pilot study. Eur J Clin Invest. 2007;37:852-859.
176. Zhang M, Perino A, Ghigo A, et al. NADPH oxidases in heart failure: poachers or gamekeepers? Antioxid Redox Signal. 2013;18:1024-1041.
177. Chakrabarti AK, Feeney K, Abueg C, et al. Rationale and design of the EMBRACE STEMI study: A phase 2a, randomized, double-blind, placebo- controlled trial to evaluate the safety, tolerability and efficacy of intravenous bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013;165:509-514.
178. Dolinsky VW, Chakrabarti S, Pereira TJ, et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta. 2013;1832:1723-1733.
179. Ritchie RH, Irvine JC, Rosenkranz AC, et al. Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO∗ and beyond. Pharmacol Ther. 2009;124:279-300.
180. Fiedler B, Lohmann SM, Smolenski A, et al. Inhibition of calcineurin- NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99:11363-11368.
181. Vandenwijngaert S, Pokreisz P, Hermans H, et al. Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. PLoS One. 2013;8:58841.
182. Burnett JC Jr. Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: What is on the horizon. J Cardiol. 2006;48: 235-241.
183. Rosenkranz AC, Woods RL, Dusting GJ, et al. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: Importance of cyclic GMP. Cardiovasc Res. 2003;57:515-522.
184. Gassanov N, Biesenbach E, Caglayan E, et al. Natriuretic peptides in therapy for decompensated heart failure. Eur J Clin Pharmacol. 2012; 68:223-230.
185. Birner C, Ulucan C, Bratfisch M, et al. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2012; 385:1117-1125.
186. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
187. Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: The first decade. Int J Hypertens. 2012;2012:307315.
188. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401-414.
189. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet. 2012;380: 1387-1395.
190. McDonald KM, Francis GS, Matthews J, et al. Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. J Am Coll Cardiol. 1993;21:514-522.
191. Ruiz-Hurtado G, Delgado C. Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors. J Hypertens. 2010; 28(suppl 1):56-61.
192. Irvine JC, Cao N, Gossain S, et al. HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyo- cytes: potential therapeutic advantages of HNO over NO. Am J Physiol Heart Circ Physiol. 2013;305:365-377.
193. Lee DI, Vahebi S, Tocchetti CG, et al. PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol. 2010;105:337-347.
194. Niu X, Watts VL, Cingolani OH, et al. Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol. 2012;59:1979-1987.
195. Kulandavelu S, Hare JM. Alterations in beta3-adrenergic cardiac innervation and nitric oxide signaling in heart failure. J Am Coll Cardiol. 2012;59:1988-1990.
196. Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755-768.
197. Geschka S, Kretschmer A, Sharkovska Y, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One. 2011;6:21853.
198. Masuyama H, Tsuruda T, Sekita Y, et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res. 2009;32:597-603.
199. Irvine JC, Ganthavee V, et al. The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy. PLoS One. 2012;7:44481.
200. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222.
201. Blanton RM, Takimoto E, Lane AM, et al. Protein kinase g ialpha inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc. 2012;1:003731.
202. Westermann D, Becher PM, Lindner D, et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol. 2012;107:308.
203. Zeidan A, Siam A, Al KA, et al. The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38. Can J Physiol Pharmacol. 2012;90:1247-1255.
204. Kristek F, Koprdova R, Cebova M. Long-term effects of early administered sildenafil and NO donor on the cardiovascular system of SHR. J Physiol Pharmacol. 2007;58:33-43.
205. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA. 2013;309:1268-1277.
206. Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122:717-728, 18.
207. Haschke M, Schuster M, Poglitsch M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52:783-792.
208. Gomes ER, Santos RA, Guatimosim S. Angiotensin-(1-7)-mediated signaling in cardiomyocytes. Int J Hypertens. 2012;2012:493129.
209. Zeng WT, Chen WY, Leng XY, et al. Impairment of cardiac function and remodeling induced by myocardial infarction in rats are attenuated by the nonpeptide angiotensin-(1-7) analog AVE 0991. Cardiovasc Ther. 2012;30:152-161.
210. Marques FD, Ferreira AJ, Sinisterra RD, et al. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension. 2011;57:477-483.
211. Savergnini SQ, Ianzer D, Carvalho MB, et al. The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. PLoS One. 2013;8:57757.
212. Kim M, Shen M, Ngoy S, et al. AMPK isoform expression in the normal and failing hearts. J Mol Cell Cardiol. 2012;52:1066-1073.
213. Zhang CX, Pan SN, Meng RS, et al. Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats. Clin Exp Pharmacol Physiol. 2011;38:55-62.
214. Li HL, Yin R, Chen D, et al. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overloadinduced cardiac hypertrophy. J Cell Biochem. 2007;100:1086-1099.
215. Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 2002;109:357-362.
216. DeBosch B, Treskov I, Lupu TS, et al. Akt1 is required for physiological cardiac growth. Circulation. 2006;113:2097-2104.
217. DeBosch B, Sambandam N, Weinheimer C, et al. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem. 2006;281: 32841-32851.
218. Wang L, Wang X, Proud CG. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Am J Physiol Heart Circ Physiol. 2000;278:1056-1068.
219. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002;99:907-912.
220. von Lewinski D, Voss K, Hulsmann S, et al. Insulin-like growth factor- 1 exerts Ca2+-dependent positive inotropic effects in failing human myocardium. Circ Res. 2003;92:169-176.
221. McMullen JR, Amirahmadi F, Woodcock EA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A. 2007;104:612-617.
222. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev. 2002; 7:175-185.
223. Cittadini A, Monti MG, Iaccarino G, et al. Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling. Gene Ther. 2006;13:8-19.
224. McLean BA, Zhabyeyev P, Pituskin E, et al. PI3K inhibitors as novel cancer therapies: Implications for cardiovascular medicine. J Card Fail. 2013;19:268-282.
225. Gao XM, Wong G, Wang B, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens. 2006; 24:1663-1670.
226. Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates loadinduced cardiac hypertrophy in mice. Circulation. 2003;107:1664-1670.
227. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307: 1098-1101.
228. Schaffer SA, Ross HJ. Everolimus: efficacy and safety in cardiac transplantation. Expert Opin Drug Saf. 2010;9:843-854.
229. Le CP, Hittinger L, Chanson P, et al. Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. J Clin Endocrinol Metab. 2007;92:180-185.
230. Tritos NA, Danias PG. Growth hormone therapy in congestive heart failure due to left ventricular systolic dysfunction: A meta-analysis. Endocr Pract. 2008;14:40-49.
231. Konstam MA. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol. 2005;96:867-871.